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SEARCH FOR WATER-SOLUBLE, NONTOXIC 
FULLERENE DERIVATIVES TO INHIBIT HIV-I 
PROTEASE ACTIVITY 
by Christopher J. Leichliter 
Until recently it was thought that pure carbon existed in only two forms 
or allotropes, named graphite and diamond. The difference between the two 
allotropes can be found in the arrangement of carbon atoms to each other. 
Graphite is a soft, black solid that conducts electricity and can be used as a 
lubricant. When graphite is subjected to extreme pressure underground for 
many years, the graphite becomes diamond, the hardest natural substance 
known. Graphite is composed of sheets of six-membered rings that are sp2-
hybridized, allowing for electrons to flow along the sheets and for the sheets 
to slide past each other. Diamond is tetrahedrally arranged in a three-
dimensional crystal network. The structures of graphite and diamond help to 
explain the characteristics of the allotropes.1 In 1985 chemists at Rice 
University discovered another stable allotrope of carbon which possessed the 
molecular formula C6o· This new form of carbon subsequently became 
known as the fullerene. 
The discovery of fullerenes, otherwise known as buckyballs, has produced 
an extensive search into the possible applications of this unique form of 
carbon. Spherically shaped, this hollow cluster of carbon atoms has special 
properties that include heat resistance and electrical conductivity, making it a 
possible candidate for semiconductors, micro-filters, and high temperature 
lubricants.2 Another property of this molecule is its hydrophobic nature 
which can be exploited for its interactions with the hydrophobic cleft found in 
the active site of some enzymes. The enzyme HIV-protease possesses an 
active site that resembles the size and shape of the C6o fullerene.3 Studies 
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have indicated that the active site is a hollow hydrophobic cylinder with 
Aspartate 25 and Aspartate 125 acting as polar catalytic groups.4 If the 
fullerene were to become lodged in the active site of the enzyme, the protease 
would become inactivated, thus hindering the spread of the virus. This paper 
discusses the research conducted to discover and produce a water-soluble, 
nontoxic fullerene derivative to inhibit HIV-1 protease activity. 
Using computer molecular modeling, a team of researchers at the 
University of California San Francisco5 made models of C6o and the protease 
enzyme. After minimizing the models, the fullerene was fitted into the active 
site of the enzyme using a program called DOCK3. This program aligns the 
fullerene with the active site by optimizing the ligandreceptor interactions of 
the van der Waals contacts and complementary electrostatics.6 The lowest 
energy conformer was selected for subsequent energy studies. An estimation 
of the energy associated with this interaction can be approximated by 
calculating the difference in solvent-exposed surface area between the open 
active site and the C6o I enzyme complex. Once bound, the fullerene 
effectively removes 298 A2 of surface area from solvent contact. This 
calculation corresponds to a free energy gain of approximately 8-12 kcal/mol 
for the bound complex. 7 A few of the other factors involved in the energetics, 
including the aspartate interactions with the C6o surface and the 
conformational energy of the bound complex, were left out of the estimation 
for simplicity. The dissociation constant Ki can be estimated using the 
relationship ~Gbind = -RTln Ki, producing a constant of about 10-6 to 10-9 M. 
Other HIV protease inhibitors, as Friedman notes, lie in the subnanomolar 
range (peptide based) and high nanomolar range of concentrations 
(nonpeptide based). Lower dissociation constants indicate tighter binding of 
the enzyme-inhibitor complex, which is necessary for removal of active 
enzyme. 
The problem surrounding the use of C6o centers on its hydrophobicity, 
making it insoluble in a water environment. Solubility can be achieved, 
however, if the fullerene possesses polar substituents that can interact with the 
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water solvent. Researchers have constructed several derivatives, with varying 
potency, to test against HIV activity.8 The first attempt to create a water-
soluble, thermally stable fullerene derivative in the range of physiological pH 
produced bis (phenethylamino-succinate) C6o.9 This compound was produced 
via cycloaddition to the fullerene with a diphenyldiazomethane derivative. 
After creating the first anti-HIV fullerene derivative, Friedman calculated the 
Ki to be 5 .3 µM for the competitive inhibitor. Emory University School of 
Medicine's Schinazi tested this derivative with HIV infected human 
lymphocytes to obtain an ECso of,.., 6 µM.10 (ECso indicates the effective 
enzyme concentration with 50% maximum activity.) 
Many people infected with HIV can attest that the treatment of the virus 
can be as painful as the actual infection. The adverse reactions associated 
with the most effective drugs can be related to the cytotoxicity of the drug on 
uninfected cells. Using peripheral blood mononuclear cells, H9 cells, Vero 
cells, and CEM cells, Schinazi found the fullerene derivative to be nontoxic 
up to a concentration of 100 µM. This indicates that most of the first 
generation fullerene derivatives are comparatively safe for regular functioning 
cells. 
Currently the search for HIV inhibition with fullerenes involves the 
discovery of novel substituents to attach to the fullerene. One group sought 
to improve the substituent by using a pentapeptide known to display strong 
human monocyte chemotaxis.11 This peptide sequence induces monocyte 
migration, which would concentrate the fullerene derivative around the cells 
that are attacked by the HIV virus. Preliminary results indicate similar anti-
viral activity compared to other fullerene derivatives. These peptide-
fullerenes will probably dominate the newly synthesized derivatives in the 
search for better inhibitors. 
While the results using the current "first generation" fullerene derivatives 
are promising, they still lack the potency of current anti-HIV technology.12,13 
There are problems with protease inhibition that make it difficult to find any 
effective inhibitor for the HIV protease enzyme. As Schinazi explains, the 
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manufactured drug must be resistant to enzyme degradation and possess a low 
protein binding affinity. It must also be able to penetrate the virus membrane 
or be at sufficient concentration near the cell membrane prior to virus 
budding. These obstacles make the search for potent inhibitors very difficult. 
The use of C6o to produce an HIV inhibitor is a novel approach in the 
search for new uses of fullerenes. With the Nobel Prize for Chemistry 
recently awarded to the discoverers of fullerenes, it is apparent that this new 
form of carbon has become an interesting topic for research throughout the 
sciences.14 Although the current biological applications of C6o are limited, 
this field promises to produce an exciting aray of new discoveries. 
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